ALEMBIC LABS
← back to folds

distillation №80

BPC-157 — Double substitution within the C-terminal pharmacophore: Asp-10 → L-homoarginine (hArg) AND Asp-11 → L-homoarginine (hArg), converting the tandem acidic DD motif into a tandem basic (hArg-hArg) motif while preserving backbone length and the AGLV hydrophobic tail

DOUBLE SUBSTITUTION WITHIN THE C-TERMINAL PHARMACOPHORE: ASP-10 → L-HOMOARGININE (HARG) AND ASP-11 → L-HOMOARGININE (HARG), CONVERTING THE TANDEM ACIDIC DD MOTIF INTO A TANDEM BASIC (HARG-HARG) MOTIF WHILE PRESERVING BACKBONE LENGTH AND THE AGLV HYDROPHOBIC TAILREGENERATIVEMay 5, 2026[ DISCARDED ]
[↓ download report.pdf]
average confidence
63.1%
pTM
0.3534715175628662
ipTM
0.22291216254234314
binding Δ
—
agreement
—
target
Vascular endothelial growth factor receptor 2
uniprot
P35968
01/

3D structure

// booting Mol* viewer

// powered by Mol* — drag to rotate · scroll to zoom · use the right panel for cartoon / spacefill / surface presets, measurements & export

chain A — peptide (plasma red)chain B+ — target / context (white)
02/

AI analysis

tldr

—

detailed analysis

—

03/

research data

A

known activity

// not yet provided by clinical agent

B

biohacker use

// not yet provided by clinical agent

C

mechanism class

// not yet provided by clinical agent

05/

folding metrics

// no per-residue pLDDT trace — Boltz-2 returned summary metrics only

aggregation propensity (window)

15 windows

confidence metrics

pLDDT mean
0.63
pTM
0.35
ipTM
0.22
Boltz ↔ Chai
—
cross-validated (borderline pLDDT)
06/

domain annotations

// not yet annotated by clinical / structural agents

07/

structural caption

No reliable 3D structure could be obtained for this peptide.

08/

peptide profile

These are sequence-based heuristic estimates, not wet-lab measurements. Real aggregation propensity requires TANGO/Aggrescan, real BBB permeability requires QSAR models, and real half-life requires PK studies. Treat the numbers as ranked indicators — useful for comparing variants, not for absolute claims.

aggregation propensity
heuristic
0.200
● good
Predicted likelihood of self-aggregation. Lower is better.
≤ 0.40 good · ≤ 0.80 moderate
source: Kyte-Doolittle window proxy
stability prediction
heuristic
0.59
● moderate
Composite stability score. Higher = more stable in solution.
≥ 0.70 good · ≥ 0.40 moderate
source: charge / proline / length composite
BBB penetration
heuristic
0.220
● moderate
Estimated blood-brain barrier permeability. Goal depends on target tissue.
≥ 0.50 high · ≥ 0.20 moderate
source: hydrophobic fraction proxy
half-life estimate
heuristic
moderate-to-long (~1–6 hours)
● —
In-silico estimated plasma half-life range.
text estimate
source: length-bucket heuristic
09/

known binders

// no ChEMBL binders found for this target

11/

agent findings

3 findingslast updated: 2026-05-05 04:07:08 UTC
researcher: 1literature: 1structural: 1
☿RESEARCHER agentclaude-opus-4-7
2026-05-05 03:59:07 UTC· 19.8s● COMPLETED
Double substitution within the C-terminal pharmacophore: Asp-10 → L-homoarginine (hArg) AND Asp-11 → L-homoarginine (hArg), converting the tandem acidic DD motif into a tandem basic (hArg-hArg) motif while preserving backbone length and the AGLV hydrophobic tail
🜍LITERATURE agentclaude-sonnet-4-6
2026-05-05 03:59:27 UTC· 1m 18s● COMPLETED
9 PubMed + 3 preprints synthesised
🜔STRUCTURAL agentclaude-opus-4-7
2026-05-05 04:00:45 UTC· 6m 23s● COMPLETED
Both structure predictors failed to produce usable output for this peptide. Marking as failed.
12/

caveats

  • ─in silico prediction only — requires wet lab validation
  • ─single-run prediction (not ensembled)
  • ─predicted properties may not reflect biological reality
  • ─this is research, not medical advice
  • ─modified peptides have not been synthesized or tested
13/

data

[↓ download fold.json][↓ download structure.pdb][⊘ on-chain unavailable][⎘ copy permalink]
14/

works cited

  1. [1]

    (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.

    · PubMed PMID ↗

  2. [2]

    (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.

    · PubMed PMID ↗

  3. [3]

    (2025). BPC-157 Binding to SH3 Domains and Activation of Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Production

    · PubMed PMID ↗

  4. [4]

    (2025). BPC-157 Predicted to Bind SH3 Domains and Activate Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Validation

    · PubMed PMID ↗

  5. [5]

    (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.

    · PubMed PMID ↗

  6. [6]

    (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.

    · PubMed PMID ↗

  7. [7]

    (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.

    · PubMed PMID ↗

  8. [8]

    (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.

    · PubMed PMID ↗

  9. [9]

    (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.

    · PubMed PMID ↗

  10. [10]

    (2022). Pentadecapeptide BPC 157 and the central nervous system.

    · PubMed PMID ↗

  11. [11]

    (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    · PubMed PMID ↗

  12. [12]

    (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.

    · PubMed PMID ↗